SITC 2021 | Benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma

Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma previously treated with these agents. A recent retrospective review in 26 patients showed that the best overall response (BOR) rate was 74% after this first ipilimumab/nivolumab but only 23% after reinduction. Only 4% In patients who had an objective response during the first course responded to reinduction and only one of five patients who did not respond to the first course responded to reinduction. Time to treatment failure (TTF) was 5.4 months after reinduction for all patients and was shorter for reinduction than for the first course in 85% of patients. Median overall survival (OS) from reinduction was 8.4 months. Finally, reinduction was associated with fewer immune-related adverse events. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.